US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% META $721.31 ▼-2.38%
FinancialContent

Articles published by Can-Fite BioPharma Ltd.

< Previous 1 2 3 4 5 Next >
News headline image
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Provides Update on Clinical and Financial Status
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >